Immtech Pharmaceuticals, Inc.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Holding
- Established
- 1984-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.immtechpharma.com
Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2008-12-08
- Lead Sponsor
- Immtech Pharmaceuticals, Inc
- Target Recruit Count
- 111
- Registration Number
- NCT00803933
- Locations
- π¨π¬
CDTC Maluku, Gombe, Kinshasa, Congo
π¨π¬Vanga Hospital, Gombe, Kinshasa, Congo
A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2008-12-05
- Lead Sponsor
- Immtech Pharmaceuticals, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT00802594
- Locations
- π¦π΄
Laboratory of Reference and Investigation, Viana, ICCT, Bairro Ingombota, Luanda, Angola
π¨π¬Programme National de Lutte contre la Trypanosomiase, Kinshasa, Gombe, Congo
Randomized, Double-Blind Phase 1 Safety and Tolerability Study of Pafuramidine Maleate (DB289) in Healthy Subjects
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- Immtech Pharmaceuticals, Inc
- Target Recruit Count
- 100
- Registration Number
- NCT00619346
- Locations
- πΏπ¦
Farmovs-Parexel, Bloemfontein, Republic of South Africa, South Africa
Prophylactic Antimalarial Activity of DB289 in Volunteers
Phase 1
Completed
- Conditions
- Prophylactic Activity Against Malaria
- First Posted Date
- 2006-12-06
- Last Posted Date
- 2008-01-29
- Lead Sponsor
- Immtech Pharmaceuticals, Inc
- Target Recruit Count
- 19
- Registration Number
- NCT00408369
- Locations
- πΊπΈ
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)
Phase 3
Terminated
- Conditions
- Pneumonia, Interstitial Plasma CellPneumocystis Carinii PneumoniaPneumonia, Pneumocystis CariniiHIV Infections
- Interventions
- Drug: Trimethoprim-Sulfamethoxazole (TMP-SMX)
- First Posted Date
- 2006-03-14
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- Immtech Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT00302341
- Locations
- πΊπΈ
University of Cincinnati, Cincinnati, Ohio, United States
πΊπΈUNC AIDS Clinical Trials, Chapel Hill, North Carolina, United States
πΊπΈHenry Ford Health System, Detroit, Michigan, United States
Β© Copyright 2025. All Rights Reserved by MedPath